Health Economics Course 2024 (16/09/2024 – 31/10/2024)
Registration is now open! Follow this link to register.
For a decade the EHC has provided NMOs and a wider community with education on the evolution of health economics, tender process, and procurement in bleeding disorders.
From the first face-to-face meeting in London in 2013, health technology assessments (HTA) have become commonplace in national healthcare systems and bleeding disorders. The ability for an individual patient to input into horizon scanning, model inputs and design, procurement methods, and reporting is increasing with HTA agencies improving their engagement processes. The EHC aims to ensure access to education for patients and patient organisations on-demand for engaging in health technology assessments. As a result, in 2023, the EHC decided to create an online educational course on Health Economics in Europe.
We invite all rare bleeding disorders patients to enrol in this course. The programme may also act as a quick reference guide for students, researchers, and HTA agencies to begin to understand the issues related to bleeding disorders and how to evaluate them. Please note that the industry representatives will not be accepted as attendees.
Why you should take this course:
-> Overall rating of the course in 2023 was positively assessed by 100% of the respondents! excellent (43,8%), very good (37,5%), and good (18,7%)!
-> The content of the course 2023 was evaluated positively by 93,8% of the respondents!
What people say about our previous edition:
“I liked the breadth and depth of the concepts with practical relevant examples”
“It was very useful to hear about the systems in different countries and to see the cost/life years statistics”
“All concepts are in one place. Very well-explained definitions and their applications in our field”
- Learning how to analyse various treatments and assess their value.
- Understanding how HTA bodies assess treatments and ways to impact this evaluation.
- Helping your government in ensuring treatment access for patients with bleeding disorders.
- Exploring ways to balance innovative treatments with budget limitations.
A tip from last year’s attendees: dedicate time every day to learning to achieve the best results!
The programme of this course is held online, consisting of sequential webinars (for self-education) with additional interactive materials to improve personal and NMO knowledge.
Programme (subject to review):
Module 4 – Payment Models
For any questions, please contact us at [email protected].
The EHC thanks the following sponsors – Pfizer, Sanofi, and Sobi – for supporting this project.
* This educational course is for educational purposes only, does not endorse or promote any specific pharmaceutical organisation, drug or other medical intervention, and has been developed, created, and delivered by the EHC in collaboration with Prime HCD experts independently from sponsors of this project.
Jim is aged 66 and has Haemophilia A with a high titer inhibitor which he developed at age 14.
Maria Elisa Mancuso (MD, PhD) is a Haematologist and works as a Senior Haematology Consultant at the Center for Thrombosis and Haemorrhagic Diseases of IRCCS Humanitas Research Hospital in Rozzano, Milan, Italy. She is Adjunct Clinical Professor at Humanitas University. She obtained a post-degree in Clinical and Experimental Haematology and a PhD in Clinical Methodology. She is involved in clinical research and has published several original articles in peer-reviewed journals a The Lancet, Blood, Journal of Thrombosis and Haemostasis, Haematologica, Thrombosis and Haemostasis, British Journal of Haematology and Haemophilia. She is reviewer for several peer-reviewed journals and member of the Editorial Board of JTH. She is a member of several scientific societies (ISTH, WFH, ASH, EAHAD, SISET, AICE) and was a medical member of the Inhibitor Working Group of the European Hemophilia Consortium. She is co-chair of the ADVANCE Study Group. She has acted also as co-chair of the Scientific and Standardization Subcommittee of ISTH on FVIII, FIX and rare bleeding disorders. She has been involved as principal and co-investigator in several clinical trials, and she takes care of both children and adults with hemophilia and other congenital bleeding disorders with a specific scientific interest in novel therapies, prophylaxis, inhibitors, and chronic hepatitis C.
As a patient with factor II deficiency, the diagnostic and treatment of rare bleeding disorders is a matter dear to my heart. My motivation to participate in the work of the ERIN committee is to improve both diagnostic and treatment for patients with rare bleeding disorders across Europe.
Economist and financial expert by profession, executive coach and trainer by passion and haemophilia advocate by every drop of my blood through my son (who has severe haemophilia A with inhibitors). Bringing a good decade of practical experience from the corporate insurance world, laser focus, growth mindset and resilience from my own experience, offering you anything I can just do, in hope that together we can make life more fulfilled for those impacted by bleeding disorders.
Amy Owen-Wyard is a Registered Mental Health Nurse. With experience working with children, young people, their families and adults with severe and enduring mental health conditions. Amy was also involved in a service improvement to provide a holistic care approach for those in general hospitals to support both their mental and physical health, whilst sharing her expertise and knowledge in mental health with the wider multidisciplinary team.
